alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
---

---

Exhibit 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of PremierWest Bancorp (the "Company") on Form 10-Q for the quarter ending March 31, 2006, as filed with the Securities and Exchange
Commission on the date hereof (the "Report"), I, John L. Anhorn, the President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

|1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                                                       
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|  
|2. | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company for the period certified.
|  

This certification is being furnished solely to comply with the requirements of 18 U.S.C. Section 1350, and shall not be incorporated by reference into any of the Company's filings under the Securities Act of 1933 or the
Securities Exchange Act of 1934, or otherwise be deemed to be filed as part of the Report or under such Acts.

|Date: |  | May 5, 2006 |  | /s/ JOHN L. ANHORN                   
|----- |  | ----------- |  | -------------------------------------
|      |  |             |  | John L. Anhorn                       
|      |  |             |  | President and Chief Executive Officer

---

---
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
Hercules Incorporated 10K95
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-END>                               DEC-31-1995
<CASH>                                          72,941
<SECURITIES>                                         0
<RECEIVABLES>                                  425,865
<ALLOWANCES>                                         0
<INVENTORY>                                    308,080
<CURRENT-ASSETS>                               867,133
<PP&E>                                       2,564,240
<DEPRECIATION>                               1,564,543
<TOTAL-ASSETS>                               2,493,478
<CURRENT-LIABILITIES>                          686,721
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        78,992
<OTHER-SE>                                   1,176,846
<TOTAL-LIABILITY-AND-EQUITY>                 2,493,478
<SALES>                                      2,427,180
<TOTAL-REVENUES>                             2,427,180
<CGS>                                        1,591,715
<TOTAL-COSTS>                                2,064,187
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              28,383
<INCOME-PRETAX>                                504,643
<INCOME-TAX>                                   171,893
<INCOME-CONTINUING>                            332,750
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   332,750
<EPS-PRIMARY>                                     2.93
<EPS-DILUTED>                                        0
        

</TABLE>
Anplwaye Fabrikasyon yo

Bagay ou ka fè andedan ak andeyò travay pou pwoteje tèt ou ak pou pwoteje kòlèg travay ou kont COVID-19

CS 316954-F 06/29/2020

RETE LAKAY OU si ou malad. 

Sentòm pou ou siveye yo:

• Tous

• Souf kout oswa difikilte pou respire

• Lafyèv

• Frison

• Doulè nan misk

• Malgòj

• Vin pa ka pran gou oswa pran sant

Evite kontak avèk lòt moun pandan ou malad

• Rete nan yon chanm byen presi lakay ou epi lwen lòt moun otank posib

• Pale avèk yon doktè ak sipèvizè w konsènan lè ou kapab retounen travay

Vèsyon aksesib: https://www.cdc.gov/coronavirus/2019-ncov/community/guidance-manufacturing-workers-employers.html

cdc.gov/coronavirus

6 pye 

(2 mèt)

Rete omwen 6 pye distans (apeprè 2 longè bra yon adilt) ak lòt moun nan travay an 

nan kominote ou otank posib

• Rete omwen 6 pye distans pandan konvèsasyon, nan vestyè yo, nan koulwa oswa nan 

koridò yo, ak lè w ap antre oswa kite espas travay ou

• Pa pataje bwason oswa manje avèk kòlèg travay yo 

• Zouti yo dwe netwaye ak dezenfekte regilyèman, sitou lè ou chanje pòs travay oswa 

deplase al nan yon nouvo seri zouti

• Pa fè aranjman yon sèl vwati, si sa posib

Mete yon pwoteksyon figi an twal sou bouch ak sou nen ou pandan ou nan espas 

travay la ak an piblik

• Ajiste pwoteksyon ou an yon fason ki sere, men ki byen alèz, sou kote figi ou

• Lè w ap retire pwoteksyon figi ou an, eseye pou pa touche zye, nen, oswa bouch ou, epi 

apre sa lave men w touswit 

• Lave oswa ranplase pwoteksyon figi an aprè ou fin itilize l

• Ranplase pwoteksyon figi an lè li mouye oswa sal

• Kontinye mete ekipman pwoteksyon pèsonèl (Personal Protective Equipment, PPE) ki 

obligatwa pou djòb nòmal travay ou
cdc.gov/coronavirus

Pa touche zye, nen, oswa bouch ou

• Ak men ki pa lave

• Pandan ou mete gan 

• Pandan w ap regle oswa retire pwoteksyon figi oswa linèt sekirite ou yo

Lave men ou avèk savon ak dlo pandan omwen 20 segonn oswa sèvi avèk yon dezenfektan 

pou men abaz alkòl ki gen omwen 60% alkòl ladan:

• Avan ak aprè peryòd travay oswa poz yo

• Aprè ou fin mouche nen w, touse, oswa etènye

• Apre itilizasyon twalèt

• Anvan ou manje

• Anvan ak aprè preparasyon manje

• Aprè ou fin mete, touche, oswa retire pwoteksyon figi an twal yo.

Kouvri tous ak etènye ou

• Kouvri bouch ou ak nen ou avèk yon klinèks oswa itilize andedan koud bra ou si ou pa 

gen klinèks

• Jete klinèks ize yo nan fatra

• Touswit lave men w oswa itilize dezenfektan pou men ki gen ladan omwen 60% alkòl aprè 

ou fin etènye oswa touse
### §§571a, 571b. Omitted

#### **Editorial Notes**

#### Codification

Section 571a, Pub. L. 85–77, title II, July 1, 1957, 71 Stat. 270, which related to maximum allowance on construction costs, was from the Department of the Interior and Related Agencies Appropriations Act, 1958, and was not repeated in subsequent appropriation acts.

Section 571b, Pub. L. 85–439, title II, June 4, 1958, 72 Stat. 167, which related to maximum allowance for building improvements, was from the Department of the Interior and Related Agencies Appropriation Act, 1959, and was not repeated in subsequent appropriation acts.

#### Prior Provisions

Provisions similar to former section 571a of this title were carried in following prior appropriation acts:

June 13, 1956, ch. 380, title II, 70 Stat. 268.

June 16, 1955, ch. 147, title II, 69 Stat. 153.

June 29, 1954, ch. 409, title I, 68 Stat. 307.

July 28, 1953, ch. 251, title I, 67 Stat. 211.

July 5, 1952, ch. 574, title I, 66 Stat. 342.

Aug. 31, 1951, ch. 374, title I, 65 Stat. 232.

Sept. 6, 1950, ch. 896, Ch. VI, title I, 64 Stat. 665.

June 29, 1949, ch. 280, title I, 63 Stat. 337.

June 19, 1948, ch. 543, 62 Stat. 520.

July 30, 1947, ch. 356, title I, 61 Stat. 523.

June 22, 1946, ch. 445, 60 Stat. 283.

May 5, 1945, ch. 109, 59 Stat. 149.

June 28, 1944, ch. 296, 58 Stat. 442.

July 12, 1943, ch. 215, 57 Stat. 411.

July 22, 1942, ch. 516, 56 Stat. 679.

July 1, 1941, ch. 267, 55 Stat. 421.

June 25, 1940, ch. 421, 54 Stat. 545.

June 30, 1939, ch. 253, title I, 53 Stat. 954.

Provisions similar to former section 571b of this title were contained in the following prior appropriation acts:

July 1, 1957, Pub. L. 85–77, title II, 71 Stat. 270.

June 13, 1956, ch. 380, title II, 70 Stat. 268.

June 16, 1955, ch. 147, title II, 69 Stat. 153.

June 29, 1954, ch. 409, title I, 68 Stat. 309.

July 28, 1953, ch. 251, title I, 67 Stat. 213.

July 5, 1952, ch. 574, title I, 66 Stat. 343.

Aug. 31, 1951, ch. 374, title I, 65 Stat. 233.

Sept. 6, 1950, ch. 896, Ch. VI, title I, 64 Stat. 667.

June 29, 1949, ch. 280, title I, 63 Stat. 339.

June 19, 1948, ch. 543, 62 Stat. 520.

July 30, 1947, ch. 356, title I, 61 Stat. 523.

June 22, 1946, ch. 445, 60 Stat. 283.

May 5, 1945, ch. 109, 59 Stat. 152.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Company's financial statements for year ended December 31, 1997 and is
qualified in its entirety by reference to such financial statements.
</LEGEND>
<MULTIPLIER> 1,000

<S>                                        <C>
<PERIOD-TYPE>                                     YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                           9,829
<SECURITIES>                                     3,188
<RECEIVABLES>                                   76,471
<ALLOWANCES>                                     3,341
<INVENTORY>                                     26,442
<CURRENT-ASSETS>                               148,386
<PP&E>                                         249,350
<DEPRECIATION>                                 131,407
<TOTAL-ASSETS>                                 426,186
<CURRENT-LIABILITIES>                          109,767
<BONDS>                                        109,358
<COMMON>                                        37,907
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                     154,919
<TOTAL-LIABILITY-AND-EQUITY>                   426,186
<SALES>                                        562,709
<TOTAL-REVENUES>                               562,709
<CGS>                                          324,775
<TOTAL-COSTS>                                  324,775
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               8,421
<INCOME-PRETAX>                                 29,566
<INCOME-TAX>                                    12,270
<INCOME-CONTINUING>                             17,296
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    17,296
<EPS-PRIMARY>                                      .56
<EPS-DILUTED>                                      .56



</TABLE>
EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of WOM, Inc. (the "Company") on Form
10-QSB for the quarter ended December 31, 2005 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), Frederic M. Zinn, the
principal executive officer and principal financial officer, certifies pursuant
to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act
of 2002, that:

(1)   The Report fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and

(2)   The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

Dated: February 13, 2006


/s/ Frederic M. Zinn
----------------------
    Frederic M. Zinn
III 

116TH CONGRESS 

1ST SESSION S. RES. 359 

Authorizing the use of the atrium in the Philip A. Hart Senate Office 

Building for the National Prescription Drug Take Back Day, a semiannual event for the Drug Enforcement Administration. 

IN THE SENATE OF THE UNITED STATES 

OCTOBER 16, 2019 

Mr. SCHUMER (for himself, Ms. KLOBUCHAR, and Mr. BLUNT) submitted the 

following resolution; which was considered and agreed to 

RESOLUTION 

Authorizing the use of the atrium in the Philip A. Hart 

Senate Office Building for the National Prescription 

Drug Take Back Day, a semiannual event for the Drug 

Enforcement Administration. 

1 Resolved, 

2 SECTION 1. USE OF THE ATRIUM IN THE HART SENATE OF3 FICE BUILDING FOR TAKE BACK DAY. 

4 (a) AUTHORIZATION.—The atrium in the Philip A. 

5 Hart Senate Office Building is authorized to be used on 

6 October 23, 2019, for the National Prescription Drug 

7 Take Back Day, a semiannual event of the Drug Enforce8 ment Administration. 


pamtmann on DSKBC07HB2PROD with BILLS
2 

•SRES 359 ATS 

1 (b) PREPARATIONS.—Physical preparations for the 

2 conduct of the event described in subsection (a) shall be 

3 carried out in accordance with such conditions as may be 

4 prescribed by the Sergeant at Arms and Doorkeeper of 

5 the Senate. 

Æ 


pamtmann on DSKBC07HB2PROD with BILLS
```

[113th Congress Public Law 213]
[From the U.S. Government Publishing Office]

[[Page 128 STAT. 2086]]

Public Law 113-213
113th Congress

                                 An Act

 
To designate the facility of the United States Postal Service located at 
  10360 Southwest 186th Street in Miami, Florida, as the ``Larcenia J. 
 Bullard Post Office Building''. <<NOTE: Dec. 16, 2014 -  [H.R. 2678]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. LARCENIA J. BULLARD POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 10360 Southwest 186th Street in Miami, Florida, shall be 
known and designated as the ``Larcenia J. Bullard Post Office 
Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Larcenia J. 
Bullard Post Office Building''.

    Approved December 16, 2014.

LEGISLATIVE HISTORY--H.R. 2678:
---------------------------------------------------------------------------

CONGRESSIONAL RECORD, Vol. 160 (2014):
            Sept. 8, 10, considered and passed House.
            Dec. 8, considered and passed Senate.

                                  <all>
```
UNITED STATES OF AMERICA

before the

SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934

Release No. 85680 / April 17, 2019

Admin. Proc. File No. 3-18148

In the Matter of 

BIOPHARMA MANUFACTURING SOLUTIONS INC.,

CLTC VENTURES CORPORATION

 (N/K/A DREAMFLY PRODUCTIONS CORPORATION), 

 and

CRANE GLOBAL ENERGY COMPANY

NOTICE THAT INITIAL DECISION HAS BECOME FINAL

The time for filing a petition for review of the initial decision in this proceeding has 

expired. No such petition has been filed by BioPharma Manufacturing Solutions Inc., CLTC 

Ventures Corporation (n/k/a Dreamfly Productions Corporation), or Crane Global Energy 

Company and the Commission has not chosen to review the decision on its own initiative.

Accordingly, notice is hereby given, pursuant to Rule 360(d) of the Commission's Rules 

of Practice,1that the initial decision of the administrative law judge has become the final 

decision of the Commission with respect to BioPharma Manufacturing Solutions Inc., CLTC 

Ventures Corporation (n/k/a Dreamfly Productions Corporation), and Crane Global Energy 

Company.

2

The order contained in that decision is hereby declared final. The initial decision 

ordered that, under Section 12(j) of the Securities Exchange Act of 1934, the registration of each

 

1

 17 C.F.R. § 201.360(d).

2

 BioPharma Mfg. Solutions Inc., CLTC Ventures Corp. (n/k/a Dreamfly Prods. Corp.), Crane 

Global Energy Co., and DCA Asset Mgmt., Inc., Initial Decision Release No. 1327 (Dec. 10, 

2018), 2018 WL 6498774. The Central Index Key numbers are: 1522216 for BioPharma 

Manufacturing Solutions Inc.; 1424623 for CLTC Ventures Corporation (n/k/a Dreamfly 

Productions Corporation); and 1610839 for Crane Global Energy Company.
2

class of registered securities of BioPharma Manufacturing Solutions Inc., CLTC Ventures 

Corporation (n/k/a Dreamfly Productions Corporation), and Crane Global Energy Company is 

hereby revoked. The revocation is effective as of April 18, 2019.

For the Commission, by the Office of the General Counsel, pursuant to delegated 

authority.

Vanessa A. Countryman

 Acting Secretary
### §6233. Implementation

#### (a) Prompt implementation

The Secretary shall issue direction regarding implementation of this chapter by interim directive within 180 days after February 20, 2003. The Secretary shall implement this chapter beginning with the first billing cycle for organizational camp special use authorizations occurring more than 180 days after February 20, 2003.

#### (b) Phase-in of use fee increases

In issuing any direction regarding implementation of this chapter under subsection (a), the Secretary shall consider whether to phase-in any significant increases in annual land or facility use fees for organizational camps.

(Pub. L. 108–7, div. F, title V, §504, Feb. 20, 2003, 117 Stat. 296.)

#### **Editorial Notes**

#### References in Text

This chapter, referred to in text, was in the original "this Act", which was translated as reading "this title", meaning title V of div. F of Pub. L. 108–7, known as the National Forest Organizational Camp Fee Improvement Act of 2003, to reflect the probable intent of Congress.
# C_2009013EN.01S00301.xml

| 20.1.2009 | EN | Official Journal of the European Union | C 13/s3 |
| --- | --- | --- | --- |

20.1.2009

EN

Official Journal of the European Union

C 13/s3

---

NOTE TO THE READER

NOTE TO THE READER

The institutions have decided no longer to quote in their texts the last amendment to cited acts.

Unless otherwise indicated, references to acts in the texts published here are to the version of those acts currently in force.

---
ကုန္ထုတ္လုပ္ေရး ဝန္ထမ္းမ်ား

သင္ကိုယ္တိုင္ႏွင့္သင့္လုပ္ေဖာ္ကိုင္ဖက္မ်ားကို COVID-19 မွကာကြယ္ရန္လုပ္ငန္းခြင္အတြင္းႏွင့္လုပ္ငန္းခြင္ျပင္ပမ်ားတြင္လုပ္ေဆာင္ရမည့္အရာမ်ား

CS 316954-J 06/29/2020

ေနမေကာင္းလွ်င္အိမ္မွာ ေနပါ။

ေစာင့္ၾကည့္ရမည့္ေရာဂါလကၡဏာမ်ား -

• ေခ်ာင္းဆိုးျခင္း

• အသက္ရႉၾကပ္ျခင္း သို႔မဟုတ္အသက္ရႉရခက္ျခင္း

• ဖ်ားျခင္း

• ခ်မ္းစိမ့္ျခင္း

• ႂကြက္သားမ်ား နာက်င္ျခင္း

• လည္ေခ်ာင္းနာျခင္း

• အရသာ သို႔မဟုတ္အနံ႔ေပ်ာက္ဆုံးျခင္း

သင္ဖ်ားနာေနလွ်င္အျခားလူမ်ားႏွင့္ထိေတြ႕ျခင္းမွ ေရွာင္ရွားပါ

• အျခားသူမ်ားႏွင့္ေဝးရာေနရာ သင့္အိမ္ရွိသီးသန္႔ခန္းတြင္ျဖစ္ႏိုင္သမွ် ေနထိုင္ပါ

• သင္အလုပ္ျပန္ဆင္းႏိုင္မည့္အခ်ိန္ႏွင့္ပတ္သက္၍ သင္၏ ႀကီးၾကပ္သူ၊ ဆရာဝန္တစ္ဦးႏွင့္ေျပာဆိုေဆြးေႏြးပါ

အသုံးျပဳႏိုင္ေသာ ဗားရွင္း- https://www.cdc.gov/coronavirus/2019-ncov/community/guidance-manufacturing-workers-employers.html

cdc.gov/coronavirus

လုပ္ငန္းခြင္ႏွင့္သင္၏ ပတ္ဝန္းက်င္တြင္တတ္ႏိုင္သမွ် အျခားလူမ်ားႏွင့္ (လူႀကီး 2 ဦး၏ လက္ေမာင္းမ်ား အကြာအေဝး) အနည္းဆုံး 6 ေပခန႔္

ခြာ၍ ေနထိုင္ပါ။

• ေသာ့ခတ္ထားသည့္အခန္းတြင္၊ ေလွ်ာက္လမ္း သို႔မဟုတ္စႀကႍလမ္းႏွင့္လုပ္ငန္းခြင္သို႔သြားသည္ျဖစ္ေစ သို႔မဟုတ္ျပန္သည္ျဖစ္ေစ

စကားေျပာဆိုပါက အနည္းဆုံး 6 ေပအကြာမွ ေျပာဆိုပါ။

• လုပ္ေဖာ္ကိုင္ဖက္မ်ားႏွင့္အစားအေသာက္မွ်ေဝစားေသာက္ျခင္းကို ေရွာင္ၾကဥ္ပါ

• အထူးသျဖင့္လုပ္ငန္းခြင္ေျပာင္းလဲလွ်င္သို႔မဟုတ္ပစၥည္းကိရိယာ အသစ္မ်ားသို႔ေျပာင္းသုံးလွ်င္ပစၥည္းကိရိယာမ်ားကို ပုံမွန္

သန႔္ရွင္း၍ ပိုးသတ္ရမည္

• တတ္ႏိုင္သမွ် ကားႀကဳံလိုက္မစီးပါႏွင့္။

လုပ္ငန္းခြင္သို႔မဟုတ္လူထုၾကားထဲတြင္ရွိေနခ်ိန္၌ သင့္ႏွာေခါင္း ႏွင့္ပါးစပ္တို႔အား ဖုံးအုပ္ေပးႏိုင္သည့္အဝတ္ႏွာေခါင္းစည္းကို တပ္ထားပါ။

• သင့္အကာအကြယ္အား သင့္မ်က္ႏွာ ေဘးဘက္မ်ားႏွင့္အံကိုက္ျဖစ္ေအာင္ဝတ္ဆင္ရမည္သို႔ေသာ္သက္ေသာင့္သက္သာ ရွိရွိ

ဝတ္ဆင္ရမည္

• သင့္မ်က္ႏွာ အကာအကြယ္ကို ဖယ္ရွားလွ်င္သင့္မ်က္လုံးမ်ား၊ ႏွာေခါင္း သို႔မဟုတ္ပါးစပ္မ်ားႏွင့္မထိေတြ႕ပါေစႏွင့္၊ သင့္လက္မ်ားကို

ခ်က္ျခင္း ေဆးေၾကာပါ

• အသုံးျပဳၿပီးေနာက္ႏွာေခါင္းစည္းအား ေလွ်ာဖြပ္ပါ သို႔မဟုတ္လဲလွယ္ပါ

• စိုေနလွ်င္သို႔မဟုတ္ညစ္ေပေနလွ်င္ႏွာေခါင္းစည္းအား လဲလွယ္ပါ

• သင့္ပုံမွန္လုပ္ငန္းေဆာင္တာမ်ားအတြက္လိုအပ္သည့္တစ္ကိုယ္ေရကာကြယ္ေရးဝတ္စုံ (PPE) အား ဆက္လက္ဝတ္ဆင္ပါ

6 ပေ (2 မီတာ)
cdc.gov/coronavirus

သင့္မ်က္လုံးမ်ား၊ ႏွာေခါင္း သို႔မဟုတ္ပါးစပ္တို႔အား ေအာက္ပါတို႔ျဖင့္မထိေစရ -

• မေဆးရေသးေသာလက္မ်ားျဖင့္

• လက္အိတ္မ်ား ဝတ္ဆင္ေနစဥ္

• ႏွာေခါင္းစည္း သို႔မဟုတ္ေဘးကင္းလုံၿခဳံေရးမ်က္မွန္မ်ားအား ခ်ိန္ညႇိေနစဥ္သို႔မဟုတ္ခြၽတ္ေနစဥ္

ေအာက္ပါအေျခအေနတို႔တြင္အနည္းဆုံး စကၠန႔္ 20 ၾကာေအာင္ဆပ္ျပာႏွင့္ေရကို အသုံးျပဳၿပီးသင့္လက္ကို ေဆးေၾကာပါ သို႔မဟုတ္

အယ္လ္ကိုေဟာ အနည္းဆုံး 60% ပါဝင္သည့္အယ္လ္ကိုေဟာအေျချပဳ လက္သန႔္ေဆးရည္တစ္ခုကို အသုံးျပဳပါ-

• အလုပ္ဆိုင္းမ်ားႏွင့္နားေနခ်ိန္မ်ား မတိုင္မီႏွင့္ၿပီးေနာက္တြင္

• ႏွပ္ညႇစ္ၿပီးေနာက္၊ ေခ်ာင္းဆိုးၿပီးေနာက္သို႔မဟုတ္ႏွာေခ်ၿပီးေနာက္တြင္

• သန႔္စင္ခန္း အသုံးျပဳၿပီးလွ်င္

• အစာမစားမီတြင္

• အစားအစာ မျပင္ဆင္မီႏွင့္ျပင္ဆင္ၿပီးေနာက္တြင္

• အဝတ္စ ႏွာေခါင္းစည္းအား ဝတ္ဆင္ၿပီးေနာက္၊ ထိေတြ႕ကိုင္တြယ္ၿပီးေနာက္သို႔မဟုတ္ဖယ္ရွားၿပီးေနာက္တြင္။

ေခ်ာင္းဆိုးႏွာေခ်ရာတြင္ဖုံးကာထားပါ

• ပါးစပ္ႏွင့္ႏွာေခါင္းအား တစ္ရႉးျဖင့္ကာထားပါ သို႔မဟုတ္တစ္ရႉးစမ်ား မရွိပါက လက္ေမာင္းတံေတာင္ဆစ္အတြင္းပိုင္းကို အသုံးျပဳပါ

• အသုံးျပဳၿပီးေသာ တစ္ရႉးမ်ားကို အမႈိက္ပုံးထဲထည့္ပါ

• ႏွာေခ်ၿပီးတိုင္း သို႔မဟုတ္ေခ်ာင္းဆိုးၿပီးတိုင္း ခ်က္ျခင္းသင့္လက္မ်ားကို ေဆးေၾကာပါသို႔မဟုတ္အနည္းဆုံး အယ္လ္ကိုေဟာ 60% 

ပါဝင္သည့္လက္သန႔္ေဆးရည္ကို အသုံးျပဳပါ
### §551c–1. Limitations on prescribed burns

#### (a) In general

Except as provided in subsection (b), the Secretary shall not authorize a prescribed burn on Forest Service land if, for the county or contiguous county in which the land is located, the national fire danger rating system indicates an extreme fire danger level.

#### (b) Exception

The Secretary may authorize a prescribed burn under a condition described in subsection (a) if the Secretary coordinates with the applicable State government and local fire officials.

#### (c) Report

At the end of each fiscal year, the Secretary shall submit to Congress a report describing—

(1) the number and locations of prescribed burns during that fiscal year; and

(2) each prescribed burn during that fiscal year that was authorized by the Secretary pursuant to subsection (b).

(Pub. L. 114–275, §3, Dec. 14, 2016, 130 Stat. 1405.)

#### **Statutory Notes and Related Subsidiaries**

#### Definitions

Pub. L. 114–275, §2, Dec. 14, 2016, 130 Stat. 1405, provided that: "In this Act [enacting this section and provisions set out as a note under section 551 of this title]:

"(1) National fire danger rating system.—The term 'national fire danger rating system' means the national system used to provide a measure of fire danger according to a range of low to moderate to high to very high to extreme.

"(2) Prescribed burn.—The term 'prescribed burn' means a planned fire intentionally ignited.

"(3) Secretary.—The term 'Secretary' means the Secretary of Agriculture, acting through the Chief of the Forest Service."
<PAGE>

                                                                      EXHIBIT 23


                       CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the incorporation by reference in the Registration
Statement on Form S-3 (File No. 333-57138) and on Form S-8 (File Nos. 333-32543,
333-60311, 333-80457 and 333-32868) of The Hertz Corporation of our report dated
January 17, 2003, relating to the consolidated financial statements and
financial statement schedule, which appears in this Form 10-K.


                                              PRICEWATERHOUSECOOPERS LLP

Florham Park, New Jersey
March 18, 2003
§ 1270.6 Reservation of funds. ( a ) On October 1 of each fiscal year, if a State has not enacted or is not enforcing a law that complies with § 1270.4, FHWA will reserve an amount equal to 2.5 percent of the funds apportioned to the State for that fiscal year under each of 23 U.S.C. 104(b)(1) and (b)(2).
( b ) The reservation of funds will be made based on proportionate amounts from each of the apportionments under 23 U.S.C. 104(b)(1) and (b)(2). The State's Department of Transportation will have 30 days from the date the funds are reserved under this section to notify FHWA, through the appropriate Division Administrator, if it would like to change the distribution of the amounts reserved between 23 U.S.C. 104(b)(1) and (b)(2).